Metformin in cancer: translational challenges
- PMID: 22355097
- DOI: 10.1530/JME-12-0007
Metformin in cancer: translational challenges
Abstract
The anti-diabetic drug metformin is rapidly emerging as a potential anti-cancer agent. Metformin, effective in treating type 2 diabetes and the insulin resistance syndromes, improves insulin resistance by reducing hepatic gluconeogenesis and by enhancing glucose uptake by skeletal muscle. Epidemiological studies have consistently associated metformin use with decreased cancer incidence and cancer-related mortality. Furthermore, numerous preclinical and clinical studies have demonstrated anti-cancer effects of metformin, leading to an explosion of interest in evaluating this agent in human cancer. The effects of metformin on circulating insulin levels indicate a potential efficacy towards cancers associated with hyperinsulinaemia; however, metformin may also directly inhibit tumour growth. In this review, we describe the mechanism of action of metformin and summarise the epidemiological, clinical and preclinical evidence supporting a role for metformin in the treatment of cancer. In addition, the challenges associated with translating preclinical results into therapeutic benefit in the clinical setting will be discussed.
Similar articles
-
New perspective for an old antidiabetic drug: metformin as anticancer agent.Cancer Treat Res. 2014;159:355-76. doi: 10.1007/978-3-642-38007-5_21. Cancer Treat Res. 2014. PMID: 24114491 Review.
-
Metformin and cancer therapy.Curr Opin Oncol. 2012 Jan;24(1):103-8. doi: 10.1097/CCO.0b013e32834d8155. Curr Opin Oncol. 2012. PMID: 22123231 Review.
-
Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin.Breast. 2011 Oct;20 Suppl 3:S31-5. doi: 10.1016/S0960-9776(11)70291-0. Breast. 2011. PMID: 22015290 Review.
-
Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer.Future Oncol. 2011 Jun;7(6):727-36. doi: 10.2217/fon.11.49. Future Oncol. 2011. PMID: 21675836 Review.
-
Metformin: taking away the candy for cancer?Eur J Cancer. 2010 Sep;46(13):2369-80. doi: 10.1016/j.ejca.2010.06.012. Epub 2010 Jul 23. Eur J Cancer. 2010. PMID: 20656475 Review.
Cited by
-
Metformin: From Diabetes to Cancer-Unveiling Molecular Mechanisms and Therapeutic Strategies.Biology (Basel). 2024 Apr 27;13(5):302. doi: 10.3390/biology13050302. Biology (Basel). 2024. PMID: 38785784 Free PMC article. Review.
-
Metformin: A Dual-Role Player in Cancer Treatment and Prevention.Int J Mol Sci. 2024 Apr 6;25(7):4083. doi: 10.3390/ijms25074083. Int J Mol Sci. 2024. PMID: 38612893 Free PMC article. Review.
-
Drug-target Mendelian randomization revealed a significant association of genetically proxied metformin effects with increased prostate cancer risk.Mol Carcinog. 2024 May;63(5):849-858. doi: 10.1002/mc.23692. Epub 2024 Mar 22. Mol Carcinog. 2024. PMID: 38517045
-
Cancer Metabolism as a Therapeutic Target and Review of Interventions.Nutrients. 2023 Oct 1;15(19):4245. doi: 10.3390/nu15194245. Nutrients. 2023. PMID: 37836529 Free PMC article. Review.
-
Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer.J Clin Oncol. 2023 Dec 10;41(35):5356-5362. doi: 10.1200/JCO.23.00296. Epub 2023 Sep 11. J Clin Oncol. 2023. PMID: 37695982 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources